Print Page  Close Window


SEC Filings

8-K
OREXIGEN THERAPEUTICS, INC. filed this Form 8-K on 10/31/2018
Entire Document
 


In re: Orexigen Therapeutics, Inc.

Debtor

  

Case No. 18-10518 (KG)

Reporting Period: September 1, 2018 - September 30, 2018

 

MOR - 1b

Schedule of Debtor Bank Account Balances (1)

For the Period: September 1, 2018 - September 30, 2018

(Unaudited)

 

$ USD ‘000s
Debtor

  

Bank

   Last Four Digits
Account No.
    

Account Description

   Beginning
Balance
9/1/2018
     Ending
Balance
9/30/2018
 

Orexigen Therapeutics, Inc.

   Silicon Valley Bank      6813      General checking    $ —        $ —    

Orexigen Therapeutics, Inc.

   Silicon Valley Bank      1180      Zero-balance lockbox(2)      —          —    

Orexigen Therapeutics, Inc.

   Silicon Valley Bank      3036      Sweep account      37,483        33,542  

Orexigen Therapeutics, Inc.

   Silicon Valley Bank      7307      Utility adequate assurance      10        10  

Orexigen Therapeutics, Inc.

   Silicon Valley Bank      5177      Collateral      100        100  
           

 

 

    

 

 

 

Total Bank Account Balances

            $ 37,593      $ 33,652  
           

 

 

    

 

 

 

Notes:

 

(1)

The Consolidated Schedule of Cash Receipts and Disbursements (MOR-1) and Schedule of Disbursements by Debtor Entity (MOR-1a) represent book balances while MOR-1b represents bank balances. The balances differ primarily due to the bank’s delayed recording of intrabank activity between the general checking and sweep accounts.

(2)

Account was closed in September 2018.